Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPATools Bozkurt, Murat Fani und Virgolini, Irene und Balogova, Sona und Beheshti, Mohsen und Rubello, Domenico und Decristoforo, Clemens und Ambrosini, Valentina und Kjaer, Andreas und Delgado-Bolton, Roberto und Kunikowska, Jolanta und Oyen, Wim J G und Chiti, Arturo und Giammarile, Francesco und Sundin, Anders und Fanti, Stefano (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. European journal of nuclear medicine and molecular imaging, 44 (9). pp. 1588-1601. ISSN 1619-7089 ![]() EJNMMI 2017 Bozkurt.pdf ['document_security_info' not defined] Nur registrierte Benutzer ['summary_page:download' not defined] (379kB) KurzfassungPURPOSE & METHODS:
Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68Ga-DOTA-conjugated peptides, as well as 18F-DOPA imaging for various neuroendocrine neoplasms.
RESULTS & CONCLUSION:
The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with 68Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.
|
||||||||||||||
![]() |
|
![]() |